STOCK TITAN

[Form 4] SCYNEXIS INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

SCYNEXIS (SCYX) reported an insider transaction on a Form 4. On 10/17/2025, a company Chief Executive Officer and Director acquired 32,500 shares of common stock at $0.76 per share. Following this trade, the insider’s beneficial ownership stands at 853,098 shares, held directly.

The filing notes this total includes 4,000 shares acquired under the 2014 Employee Stock Purchase Plan on 09/05/2025.

SCYNEXIS (SCYX) ha riportato una transazione di insider su un modulo 4. Il 17/10/2025, un Chief Executive Officer and Director della società ha acquisito 32.500 azioni ordinarie a un prezzo di $0,76 per azione. A seguito di questa operazione, la proprietà benefica dell’insider ammonta a 853.098 azioni, detenute direttamente.

La dichiarazione indica che questo totale include 4.000 azioni acquisite ai sensi del 2014 Employee Stock Purchase Plan il 05/09/2025.

SCYNEXIS (SCYX) informó una transacción de insider en un Formulario 4. El 17/10/2025, un/a Director Ejecutivo y Consejero de la empresa adquirió 32.500 acciones de acciones comunes a un precio de $0.76 por acción. Tras esta operación, la propiedad beneficiosa del insider asciende a 853,098 acciones, directamente poseídas.

La presentación señala que este total incluye 4,000 acciones adquiridas bajo el Plan de Compra de Acciones para Empleados 2014 el 05/09/2025.

SCYNEXIS (SCYX)가 Form 4에 내부자 거래를 보고했습니다. 2025년 10월 17일에 회사의 최고경영자 겸 이사가 보통주 32,500주를 주당 $0.76에 취득했습니다. 이번 거래 이후 내부자의 지분 소유853,098주로, 직접 보유합니다.

해당 신고서는 이 총액에 4,000주2014년 직원 주식매수계획에 따라 2025년 9월 5일에 취득되었음을 명시합니다.

SCYNEXIS (SCYX) a déclaré une transaction d’initié sur un Formulaire 4. Le 17/10/2025, un Chief Executive Officer and Director de l’entreprise a acquis 32 500 actions ordinaires à $0,76 par action. Suite à cette opération, la propriété bénéficiaire de l’initié s’élève à 853 098 actions, détenues directement.

Le dépôt précise que ce total inclut 4 000 actions acquises dans le cadre du Plan d’Achat d’Actions pour les Employés 2014 le 05/09/2025.

SCYNEXIS (SCYX) meldete eine Insider-Transaktion auf Formular 4. Am 17.10.2025 hat ein/e Chief Executive Officer and Director des Unternehmens 32.500 Aktien Stammaktien zu $0,76 pro Aktie erworben. Nach diesem Handel beträgt die wirtschaftliche Eigentümerschaft des Insiders 853.098 Aktien, direkt gehalten.

Die Einreichung vermerkt, dass diese Summe 4.000 Aktien umfasst, die im Rahmen des 2014 Employee Stock Purchase Plan am 05.09.2025 erworben wurden.

SCYNEXIS (SCYX) أبلغت عن صفقة داخلية في نموذج 4. في 17/10/2025، قام الرئيس التنفيذي والمدير للشركة بشراء 32,500 سهماً من الأسهم العادية بسعر $0.76 للسهم. وبعد هذه الصفقة، تصبح ملكية الداخل مباشرة وتبلغ 853,098 سهماً.

تنوه الإيداع إلى أن هذا الإجمالي يشمل 4,000 سهم اكتُسبت بموجب خطة شراء أسهم الموظفين 2014 في 05/09/2025.

Positive
  • None.
Negative
  • None.

SCYNEXIS (SCYX) ha riportato una transazione di insider su un modulo 4. Il 17/10/2025, un Chief Executive Officer and Director della società ha acquisito 32.500 azioni ordinarie a un prezzo di $0,76 per azione. A seguito di questa operazione, la proprietà benefica dell’insider ammonta a 853.098 azioni, detenute direttamente.

La dichiarazione indica che questo totale include 4.000 azioni acquisite ai sensi del 2014 Employee Stock Purchase Plan il 05/09/2025.

SCYNEXIS (SCYX) informó una transacción de insider en un Formulario 4. El 17/10/2025, un/a Director Ejecutivo y Consejero de la empresa adquirió 32.500 acciones de acciones comunes a un precio de $0.76 por acción. Tras esta operación, la propiedad beneficiosa del insider asciende a 853,098 acciones, directamente poseídas.

La presentación señala que este total incluye 4,000 acciones adquiridas bajo el Plan de Compra de Acciones para Empleados 2014 el 05/09/2025.

SCYNEXIS (SCYX)가 Form 4에 내부자 거래를 보고했습니다. 2025년 10월 17일에 회사의 최고경영자 겸 이사가 보통주 32,500주를 주당 $0.76에 취득했습니다. 이번 거래 이후 내부자의 지분 소유853,098주로, 직접 보유합니다.

해당 신고서는 이 총액에 4,000주2014년 직원 주식매수계획에 따라 2025년 9월 5일에 취득되었음을 명시합니다.

SCYNEXIS (SCYX) a déclaré une transaction d’initié sur un Formulaire 4. Le 17/10/2025, un Chief Executive Officer and Director de l’entreprise a acquis 32 500 actions ordinaires à $0,76 par action. Suite à cette opération, la propriété bénéficiaire de l’initié s’élève à 853 098 actions, détenues directement.

Le dépôt précise que ce total inclut 4 000 actions acquises dans le cadre du Plan d’Achat d’Actions pour les Employés 2014 le 05/09/2025.

SCYNEXIS (SCYX) meldete eine Insider-Transaktion auf Formular 4. Am 17.10.2025 hat ein/e Chief Executive Officer and Director des Unternehmens 32.500 Aktien Stammaktien zu $0,76 pro Aktie erworben. Nach diesem Handel beträgt die wirtschaftliche Eigentümerschaft des Insiders 853.098 Aktien, direkt gehalten.

Die Einreichung vermerkt, dass diese Summe 4.000 Aktien umfasst, die im Rahmen des 2014 Employee Stock Purchase Plan am 05.09.2025 erworben wurden.

SCYNEXIS (SCYX) أبلغت عن صفقة داخلية في نموذج 4. في 17/10/2025، قام الرئيس التنفيذي والمدير للشركة بشراء 32,500 سهماً من الأسهم العادية بسعر $0.76 للسهم. وبعد هذه الصفقة، تصبح ملكية الداخل مباشرة وتبلغ 853,098 سهماً.

تنوه الإيداع إلى أن هذا الإجمالي يشمل 4,000 سهم اكتُسبت بموجب خطة شراء أسهم الموظفين 2014 في 05/09/2025.

SCYNEXIS (SCYX) 在 Form 4 上披露了一笔内幕交易。于2025/10/17,公司 的首席执行官兼董事以每股$0.76购买了32,500股普通股。此次交易后,该内幕人的实际控制权/受益所有权853,098股,直接持有。

申报称此总额包含了4,000股,于2025/09/05通过2014员工股票购买计划获得。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Angulo Gonzalez David

(Last) (First) (Middle)
1 EVERTRUST PLAZA
13TH FLOOR

(Street)
JERSEY CITY NJ 07302

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SCYNEXIS INC [ SCYX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/17/2025 A 32,500 A $0.76 853,098(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan on September 5, 2025.
/s/ Robert F. Joyce Jr., by Power of Attorney 10/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SCYNEXIS (SCYX) report on this Form 4?

An insider who is the Chief Executive Officer and Director acquired 32,500 common shares at $0.76 on 10/17/2025.

How many SCYX shares does the insider own after the transaction?

The insider beneficially owns 853,098 shares following the reported trade.

What was the price per share for the SCYX purchase?

The purchase price was $0.76 per share.

What is the insider’s relationship to SCYNEXIS (SCYX)?

The reporting person is a Director and an Officer, serving as Chief Executive Officer.

Is the ownership direct or indirect after the SCYX transaction?

The filing lists the ownership form as Direct.

Does the total include shares from an employee plan?

Yes. The total includes 4,000 shares acquired under the 2014 Employee Stock Purchase Plan on 09/05/2025.
Scynexis

NASDAQ:SCYX

SCYX Rankings

SCYX Latest News

SCYX Latest SEC Filings

SCYX Stock Data

32.28M
41.05M
2.09%
26.58%
1.18%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
JERSEY CITY